Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
In this REDUCE-IT analysis of secondary prevention patients without diabetes at baseline, the recently defined CKM syndrome was associated with incremental CVD risk compared with MetS and normal renal function. Treatment with IPE substantially reduced CVD risk in MetS patients with renal insufficiency (i.e., CKM) and CVD.
Authors
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Michael Miller (ORCID: https://orcid.org/0000-0002-1679-2095)
- Eliot A. Brinton (ORCID: https://orcid.org/0000-0002-9807-4010)
- Armando Lira Pineda (ORCID: https://orcid.org/0000-0002-1746-3162)
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Steven B. Ketchum (ORCID: https://orcid.org/0000-0002-9302-4743)
- Terry A. Jacobson (ORCID: https://orcid.org/0000-0002-9926-2179)
- Jean‐Claude Tardif
Institutions
- Houston Methodist (US)
- Emory University (US)
- Inserm (FR)
- Université Paris Cité (FR)
- Montreal Heart Institute (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- Amarin (United States) (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Philadelphia VA Medical Center (US)
- Hôpital Bichat-Claude-Bernard (FR)
- Université de Montréal (CA)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1016/j.ajpc.2025.101387
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00